IL149640A0 - Antisense oligonucleotides - Google Patents

Antisense oligonucleotides

Info

Publication number: IL149640A0
Authority: IL; Israel
Prior art keywords: antisense oligonucleotides; inhibiting; expression; effective; wild type
Prior art date: 1999-12-15

Application number

IL14964000A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-15

Filing date

2000-12-12

Publication date

2002-11-10

2000-12-12 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-11-10 Publication of IL149640A0 publication Critical patent/IL149640A0/xx

Links

108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
239000000074 antisense oligonucleotide Substances 0.000 title 1
238000012230 antisense oligonucleotides Methods 0.000 title 1
108020004491 Antisense DNA Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000003816 antisense DNA Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

IL14964000A 1999-12-15 2000-12-12 Antisense oligonucleotides IL149640A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9929487.8A GB9929487D0 (en)	1999-12-15	1999-12-15	Antisense oligonucleotides
PCT/GB2000/004741 WO2001044455A2 (en)	1999-12-15	2000-12-12	Antisense oligonucleotides for the inhibition of expression of type i procollagen

Publications (1)

Publication Number	Publication Date
IL149640A0 true IL149640A0 (en)	2002-11-10

Family

ID=10866254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14964000A IL149640A0 (en)	1999-12-15	2000-12-12	Antisense oligonucleotides

Country Status (17)

Country	Link
US (1)	US7173122B2 (de)
EP (3)	EP2025752A3 (de)
JP (1)	JP2003516752A (de)
KR (1)	KR20020064936A (de)
CN (1)	CN1423695A (de)
AT (2)	ATE309338T1 (de)
AU (1)	AU2529701A (de)
BR (1)	BR0016347A (de)
CA (1)	CA2390674A1 (de)
DE (2)	DE60023943T2 (de)
GB (1)	GB9929487D0 (de)
IL (1)	IL149640A0 (de)
MX (1)	MXPA02005871A (de)
NO (1)	NO20022799D0 (de)
NZ (1)	NZ519008A (de)
WO (1)	WO2001044455A2 (de)
ZA (1)	ZA200203878B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7396823B2 (en) *	1999-12-15	2008-07-08	Nath Rahul K	Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
CN111378657B (zh) *	2018-12-28	2024-03-15	苏州瑞博生物技术股份有限公司	抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6265157B1 (en) *	1991-12-03	2001-07-24	Allegheny University Of The Health Sciences	Compositions and methods for detecting altered COL1A1 gene sequences
WO1993011149A1 (en)	1991-12-03	1993-06-10	Thomas Jefferson University	Methods of detecting a genetic predisposition for osteoporosis
WO1994011494A1 (en)	1992-11-09	1994-05-26	Thomas Jefferson University	Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
CA2159195A1 (en) *	1993-03-26	1994-10-13	Darwin J. Prockop	Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
DE59607750D1 (de) *	1995-03-13	2001-10-31	Aventis Pharma Gmbh	Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19508923A1 (de) *	1995-03-13	1996-09-19	Hoechst Ag	Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0736608A1 (de) *	1995-04-08	1996-10-09	Roche Diagnostics GmbH	Verfahren zur spezifischen Vervielfältigung und zum Nachweis von DNA bzw. RNA
EP0856579A1 (de) *	1997-01-31	1998-08-05	BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH	Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
US6238921B1 (en)	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
US6007995A (en) *	1998-06-26	1999-12-28	Isis Pharmaceuticals Inc.	Antisense inhibition of TNFR1 expression
BR0015507A (pt) *	1999-11-12	2002-10-22	Fibrogen Inc	Gelatinas e colágenos animais

1999
- 1999-12-15 GB GBGB9929487.8A patent/GB9929487D0/en not_active Ceased
2000
- 2000-12-12 AT AT00988966T patent/ATE309338T1/de not_active IP Right Cessation
- 2000-12-12 AU AU25297/01A patent/AU2529701A/en not_active Abandoned
- 2000-12-12 EP EP08017586A patent/EP2025752A3/de not_active Withdrawn
- 2000-12-12 AT AT05024183T patent/ATE410510T1/de not_active IP Right Cessation
- 2000-12-12 CN CN00817282A patent/CN1423695A/zh active Pending
- 2000-12-12 CA CA002390674A patent/CA2390674A1/en not_active Abandoned
- 2000-12-12 KR KR1020027007591A patent/KR20020064936A/ko not_active Withdrawn
- 2000-12-12 BR BR0016347-3A patent/BR0016347A/pt not_active Application Discontinuation
- 2000-12-12 JP JP2001545532A patent/JP2003516752A/ja active Pending
- 2000-12-12 IL IL14964000A patent/IL149640A0/xx unknown
- 2000-12-12 DE DE60023943T patent/DE60023943T2/de not_active Expired - Lifetime
- 2000-12-12 DE DE60040495T patent/DE60040495D1/de not_active Expired - Lifetime
- 2000-12-12 NZ NZ519008A patent/NZ519008A/en unknown
- 2000-12-12 US US10/149,352 patent/US7173122B2/en not_active Expired - Fee Related
- 2000-12-12 WO PCT/GB2000/004741 patent/WO2001044455A2/en not_active Ceased
- 2000-12-12 EP EP00988966A patent/EP1244781B1/de not_active Expired - Lifetime
- 2000-12-12 EP EP05024183A patent/EP1698695B1/de not_active Expired - Lifetime
- 2000-12-12 MX MXPA02005871A patent/MXPA02005871A/es unknown
2002
- 2002-05-15 ZA ZA200203878A patent/ZA200203878B/xx unknown
- 2002-06-12 NO NO20022799A patent/NO20022799D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA02005871A (es)	2002-10-23
EP1698695A2 (de)	2006-09-06
DE60023943D1 (de)	2005-12-15
EP1698695B1 (de)	2008-10-08
KR20020064936A (ko)	2002-08-10
WO2001044455A2 (en)	2001-06-21
EP1244781A2 (de)	2002-10-02
NZ519008A (en)	2004-04-30
GB9929487D0 (en)	2000-02-09
ATE410510T1 (de)	2008-10-15
CA2390674A1 (en)	2001-06-21
US7173122B2 (en)	2007-02-06
BR0016347A (pt)	2002-09-10
ATE309338T1 (de)	2005-11-15
DE60023943T2 (de)	2006-08-03
AU2529701A (en)	2001-06-25
EP2025752A2 (de)	2009-02-18
WO2001044455A3 (en)	2002-01-10
EP2025752A3 (de)	2009-08-12
EP1698695A3 (de)	2007-02-14
US20030105050A1 (en)	2003-06-05
NO20022799L (no)	2002-06-12
JP2003516752A (ja)	2003-05-20
ZA200203878B (en)	2003-08-15
DE60040495D1 (de)	2008-11-20
EP1244781B1 (de)	2005-11-09
CN1423695A (zh)	2003-06-11
NO20022799D0 (no)	2002-06-12

Publication	Publication Date	Title
DK3222722T3 (da)	2019-06-17	Antisense-design
CA2177732A1 (en)	1995-06-08	Antisense oligonucleotides having tumorigenicity-inhibiting activity
MXPA04000179A (es)	2004-03-18	Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
EP0881914A4 (de)	1999-01-07
HU9603277D0 (en)	1997-01-28	Antisense oligonucleotide modulation of raf gene expression
ATE216705T1 (de)	2002-05-15	Antisense-oligonukleotidmodulation der raf- genexpression
EP1009860A4 (de)	2002-07-10	Antisense oligonukleotid zur inhibierung von ras
DE69840748D1 (de)	2009-05-28	Verfahren zur zubereitung von antisense oligonukleotiden
HUP0104068A3 (en)	2003-09-29	Nucleotide sequences which code for the opca gene
WO2001032832A3 (en)	2001-10-18	Antisense inhibition of nucleolin expression
ATE317007T1 (de)	2006-02-15	Gene des 1-desoxy-d-xylulose-biosynthesewegs
ZA200007270B (en)	2001-06-07	Novel Nucleotide sequences coding for the zwa2 gene.
ZA200005409B (en)	2001-04-23	New nucleotide sequences which code for the eno gene.
ZA200201874B (en)	2003-08-27	Plant regulatory sequences for control of gene expression.
GB9929487D0 (en)	2000-02-09	Antisense oligonucleotides
WO2001040521A3 (en)	2002-05-16	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en)	2002-11-28	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2001291658A1 (en)	2002-03-13	Nucleotide sequences which code for the ccpa2 gene
GB0218803D0 (en)	2002-09-18	Targeted gene modification by single-standed DNA oligonucleotides
AU2001293730A1 (en)	2002-03-22	Nucleotide sequences which code for the chra gene
AU2002212255A1 (en)	2002-04-08	Nucleotide sequences which code for the trub gene
AU2002223637A1 (en)	2002-06-03	Nucleotide sequences which code for the mtra and mtrb gene
ZA200006856B (en)	2001-07-12	New nucleotide sequences which code for the pfk gene.
AU2001295470A1 (en)	2002-03-22	Nucleotide sequences which code for the gpmb gene
AU2001291729A1 (en)	2002-04-08	Nucleotide sequences which code for the cobw gene